TECENTRIQ Drug Profile

Summary for Tradename: TECENTRIQ

High Confidence Patents:	19
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for TECENTRIQ

Recent Clinical Trials for TECENTRIQ

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University Health Network, Toronto	PHASE1
Christine Ryan	Phase 2
Jun Zhang, MD, PhD	Phase 2

See all TECENTRIQ clinical trials

Pharmacology for TECENTRIQ

Mechanism of Action	Programmed Death Receptor-1-directed Antibody Interactions
Established Pharmacologic Class	Programmed Death Receptor-1 Blocking Antibody
Chemical Structure	Antibodies Antibodies, Monoclonal Antibodies, Monoclonal, Humanized

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TECENTRIQ Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TECENTRIQ Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2036-05-12	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2036-08-18	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2035-04-17	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2036-05-19	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2035-03-06	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2037-06-12	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2034-09-16	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for TECENTRIQ Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2036-06-24	Patent claims search
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2038-06-01	Patent claims search
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2038-06-01	Patent claims search
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2037-04-06	Patent claims search
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2037-09-01	Patent claims search
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2037-11-21	Patent claims search
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034		2035-11-06	Patent claims search

International Patents for TECENTRIQ

Country	Patent Number	Estimated Expiration
China	106536738
Norway	2025030
European Patent Office	3046581
Tunisia	2018000044
Japan	2020073531
European Patent Office	3430060
Hong Kong	1249533

Supplementary Protection Certificates for TECENTRIQ

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SPC/GB17/079	United Kingdom		PRODUCT NAME: ATEZOLIZUMAB; REGISTERED: UK EU/1/17/1220 20170925; UK PLGB 00031/0915 20170925; UK PLGB 00031/0908 20170925
2018/007	Ireland		PRODUCT NAME: ATEZOLIZUMAB; REGISTRATION NO/DATE: EU/1/17/1220 20170925
554	Finland
2015C/073	Belgium		PRODUCT NAME: OPDIVO; AUTHORISATION NUMBER AND DATE: EU/1/15/1014 20150626
2590018-4	Sweden		PRODUCT NAME: ATEZOLIZUMAB; REG. NO/DATE: EU/1/17/1220 20170925
2024C/526	Belgium		PRODUCT NAME: ATEZOLIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/17/1220 20170925
2017C/058	Belgium		PRODUCT NAME: ATEZOLIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/17/1220 20170925

Market Dynamics and Financial Trajectory for the Biologic Drug: TECENTRIQ (Atezolizumab)

Last updated: December 8, 2025

Executive Summary

Tecentriq (atezolizumab) is a monoclonal antibody developed by Roche that targets PD-L1, revolutionizing immuno-oncology therapies. Since its approval for multiple indications, Tecentriq has experienced significant growth driven by expanding clinical indications, geographic penetration, and commercialization strategies. This report details the current market landscape of Tecentriq, analyzes its key drivers, forecasts its financial trajectory, compares it with competitors, and highlights future growth potential amid evolving regulatory and competitive environments.

---

What is Tecentriq and How Does It Fit into the Oncology Market?

Tecentriq Overview:

• Therapeutic Class: Immune checkpoint inhibitor (PD-L1 blocker)
• Indications: Metastatic/non-small cell lung cancer (NSCLC), urothelial carcinoma, triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), extensive-stage SCLC, and other tumors.
• Launch Date: 2016 (U.S. approval for NSCLC)
• Mechanism of Action: Inhibits PD-L1, restoring T-cell activity against tumor cells.

Market Position:

• Tecentriq competes primarily with PD-1/PD-L1 inhibitors such as Keytruda (pembrolizumab), Opdivo (nivolumab), and Imfinzi (durvalumab).
• Roche’s strategic positioning leverages its robust biotech pipeline, combination therapy trials, and widespread commercialization.

---

Current Market Landscape and Key Drivers

Parameter	Details
Global Revenue (2022)	~$3.6 billion (estimated)
Market Share (PD-L1 inhibitors)	Approx. 15% (globally) among checkpoint inhibitors
Major Markets	U.S., EU5, China, Japan, emerging markets
Key Indication Revenue Breakdown (2022)	NSCLC (~45%), Urothelial Carcinoma (~20%), Breast Cancer (~10%), SCLC (~10%), Others (~15%)

Primary Market Drivers

• Expanding Indications: EPC (Early-Phase Clinical Trials) and late-stage approvals enhance market adoption.
• Combination Strategies: Use with chemotherapy, anti-CTLA-4 agents, and targeted therapies increase efficacy.
• Regulatory Approvals (2020–2022): Expanded label for small cell lung cancer, hepatocellular carcinoma, and breast cancer.
• Manufacturing and Supply Chain Optimization: Roche’s global footprint supports consistent supply and market penetration.

Market Challenges

• Competitive Landscape: Intensified competition with Keytruda, Opdivo, and emerging PD-L1 inhibitors.
• Pricing & Reimbursement: Pricing pressures and healthcare reimbursement policies vary across regions.
• Safety and Efficacy Profiles: Differentiation based on efficacy in specific populations and adverse event profiles.

---

Financial Trajectory and Revenue Forecast

Historical Revenue Trends (2018–2022)

Year	Revenue (USD billion)	Growth Rate	Major Milestones
2018	$1.5	—	First approvals for NSCLC, urothelial carcinoma
2019	$2.2	46.7%	Expanded indications, key clinical data releases
2020	$3.1	40.9%	First-line NSCLC approval, combo approvals
2021	$3.4	9.7%	Partnerships, increased market penetration
2022	$3.6	5.9%	Continued expansion, pipeline advances

Projected Revenue Growth (2023–2027)

Year	Projected Revenue (USD billion)	CAGR	Assumptions & Drivers
2023	$4.0	11%	Launch of new indications, geographic expansion
2024	$4.6	15%	Increased adoption in early-line settings
2025	$5.3	15%	Combination therapies, regulatory approvals
2026	$6.2	17%	Greater uptake in emerging markets, new indications
2027	$7.2	16%	Diversification, pipeline success

Key Revenue Drivers and Risks

Drivers	Risks
New indications (e.g., TNBC, HCC)	Regulatory delays or denials
Geographic expansion (APAC, LATAM)	Competitive pressure from alternative therapies
Combination therapy approvals	Pricing constraints and reimbursement issues
Patient access initiatives	Safety profile concerns impacting adoption

---

Competitive Analysis: How Does Tecentriq Compare?

Parameter	Tecentriq	Keytruda (Merck)	Opdivo (Bristol-Myers Squibb)	Imfinzi (AstraZeneca)
Mechanism	PD-L1 inhibitor	PD-1 inhibitor	PD-1 inhibitor	PD-L1 inhibitor
2022 Revenue (USD billion)	$3.6	$17	$8	$1.8
Main Indications	NSCLC, Urothelial, SCLC, Breast	Multiple, broad	Multiple, broad	Lung, bladder, HNSCC
Market Share	~15%	~65%	~20%	~3%
Approved Combinations	Chemotherapy, anti-CTLA-4	Multiple combos	Multiple combos	Limited

Strengths & Weaknesses

Strengths	Weaknesses
Competitive efficacy in select settings	Lower market share than Keytruda
Favorable safety profile	Limited first-line label compared to competitors
Broad global footprint	Fewer indications compared to broader competitors

---

Future Growth Opportunities and Strategic Outlook

Pipeline and Pending Approvals

• Novel Combinations: Trials with anti-CTLA-4, anti-VEGF, and targeted therapies.
• New Indications: Hepatocellular carcinoma, small cell lung cancer, and other solid tumors.
• Biomarker Development: Enhancing patient stratification via PD-L1 expression levels.

Geographic Expansion

• Expansion into emerging markets: China, Africa, Latin America.
• Local manufacturing and partnerships to mitigate tariffs, logistics.

Regulatory Environment

• Focus on fast-track and breakthrough designations globally.
• Navigating reimbursement policies, especially in cost-sensitive markets.

Partnerships & Collaborations

• Strategic alliances with biotech firms.
• Co-development in combination therapies.

---

Comparison of Market Share & Growth Strategies

Key Aspect	Tecentriq	Strategies to Accelerate Growth
Market Penetration	Focused on high-unmet need cancers	Expand to early-line treatment
Indication Expansion	Rapid approvals for additional tumors	Accelerate trials with strong preliminary data
Partnerships	Collaborations with biotech, clinical research orgs	Strengthen partnership pipeline
Pricing Strategies	Tiered pricing, patient access programs	Value-based pricing models

---

Regulatory & Policy Environment Impact

Region	Regulatory Status	Implications
U.S.	FDA approvals (since 2016), accelerated pathways	Favorable for new indications
EU	EMA approvals, NICE guidance	Reimbursement pressures, value assessments
China	NMPA approvals, local manufacturing	Rapid growth, price controls
Japan	PMDA approvals	Reimbursement based on cost-effectiveness

Key Challenges and Considerations

• Market Competition: Maintaining differentiation amid intensifying competition.
• Pricing & Reimbursement: Managing pricing power with varying healthcare policies.
• Pipeline Risks: Clinical trial outcomes, regulatory delays.
• Safety & Efficacy: Ensuring comparative advantage in adverse event profiles.

---

Conclusion

Tecentriq is positioned as a significant player in the immune-oncology market, with steady revenue growth driven by broader indications, geographic expansion, and innovative combination strategies. While faced with competitive and regulatory challenges, Roche’s emphasis on pipeline development, global reach, and partnership expansion sets the stage for sustained growth through 2027.

---

Key Takeaways

• Market Trajectory: Tecentriq’s revenues are poised to grow at a CAGR of approximately 15% from 2023 to 2027.
• Competitive Position: While currently behind Keytruda in market share, Tecentriq’s unique indications and combination therapies support competitive differentiation.
• Growth Opportunities: Expanding into early-line treatments, emerging markets, and new tumor types will be critical.
• Risks: Regulatory delays, pricing pressures, and competition remain key hurdles.
• Strategic Focus: Differentiation through biomarker-driven patient selection and combination regimens will shape future success.

---

FAQs

Q1: What are the primary indications for Tecentriq, and how are they evolving?
A1: Tecentriq is approved for metastatic NSCLC, urothelial carcinoma, TNBC, SCLC, and other solid tumors. Ongoing trials seek approval in hepatocellular carcinoma, melanoma, and other indications, broadening its potential market.

Q2: How does Tecentriq compare to Keytruda in terms of efficacy?
A2: Both drugs have demonstrated significant efficacy across similar indications; however, specific patient subgroup data and biomarker-driven outcomes vary. Head-to-head trials are limited, but Tecentriq’s niche positioning is supported by specific tumor and biomarker profiles.

Q3: What are the key risks impacting Tecentriq’s financial trajectory?
A3: Regulatory delays, increased competition, pricing and reimbursement policies, and safety concerns are primary risks. Market penetration in emerging regions also presents logistical challenges.

Q4: Which regions present the most growth opportunities for Tecentriq?
A4: China, India, Brazil, and other emerging economies offer high potential due to rising cancer incidence and expanding healthcare infrastructure, with Roche investing in local manufacturing and partnerships.

Q5: How vital are combination therapies for Tecentriq’s future?
A5: Critical. Combining Tecentriq with chemotherapy, targeted therapies, or other immunotherapies enhances its efficacy and indication spectrum, making it central to Roche’s immuno-oncology strategy.

---

References

1. [1] Roche Press Release, 2022. "Roche’s Tecentriq shows broad efficacy in tumor types across multiple clinical trials."
2. [2] IQVIA, 2022. "Global Oncology Market Insights."
3. [3] FDA, 2016. "Approval of Tecentriq for bladder cancer."
4. [4] Roche Annual Report, 2022. "Strategic developments in immuno-oncology."
5. [5] Oncology Data Bases, 2022. "PD-L1 Inhibitors Market Share."